Neuphoria Therapeutics
NEUP
8 hedge funds and large institutions have $273K invested in Neuphoria Therapeutics in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
75% less capital invested
Capital invested by funds: $1.1M → $273K (-$826K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$47K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$22.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.5K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.46K |
| 5 |
HDIM
Hanson & Doremus Investment Management
Burlington,
Vermont
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$700K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$139K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.9K |
| 4 |
Morgan Stanley
New York
|
-$240 |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$133 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
1
Lynx1 Capital Management
San Juan,
Puerto Rico
| $157K | – | – | – |
|
|
2
Jane Street
New York
| $45.7K | +$47K | +13,311 | New |
|
|
MC
3
Merck & Co
Kenilworth,
New Jersey
| $34.4K | +$35.4K | +10,027 | New |
|
|
4
Bank of America
Charlotte,
North Carolina
| $22.2K | +$22.9K | +6,484 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $10.2K | +$10.5K | +2,978 | New |
|
|
6
RhumbLine Advisers
Boston,
Massachusetts
| $3.79K | +$1.46K | +414 | +60% |
|
|
7
Morgan Stanley
New York
| $24 | -$240 | -68 | -91% |
|
|
AC
8
Armistice Capital
New York
| – | -$700K | -132,750 | Closed |
|
|
9
Point72 Asset Management
Stamford,
Connecticut
| – | -$139K | -26,333 | Closed |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$14.9K | -2,845 | Closed |
|
|
11
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$133 | -25 | Closed |
|
|
APC
12
Aspire Private Capital
Cornelius,
North Carolina
| – | -$88 | -17 | Closed |
|
|
HDIM
13
Hanson & Doremus Investment Management
Burlington,
Vermont
| – | +$4 | +1 | New |
|
NEUP Hedge Fund Activity: Q4 2024 in Review
8 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q4 2024, worth a combined $273K — down 75% from $1.1M a quarter earlier.
Fund positioning in NEUP was balanced in Q4 2024: 5 funds opened new positions, 5 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $47K. The largest seller was Armistice Capital, exiting entirely with an estimated $700K sold.
- 8 institutional investors held Neuphoria Therapeutics (NEUP) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $273K of Neuphoria Therapeutics stock for Q4 2024, down 75% quarter-over-quarter.
- 5 funds opened new Neuphoria Therapeutics positions in Q4 2024 and 5 closed out, a net change of 0 holders.
- The largest Neuphoria Therapeutics buyer in Q4 2024 was Jane Street, an estimated $47K added.
- The largest Neuphoria Therapeutics seller in Q4 2024 was Armistice Capital, an estimated $700K sold.
Based on aggregated 13F filings for Q4 2024.